Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker EVMN
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Kyle Carver Chief Financial Officer | EVMN Evommune, Inc. | Buy | 1,000 | $13.26 | $13.3K Buy | Form 4 ↗ |
| Jul 7, 2026 | Arthur S. Kirsch Director | EVMN Evommune, Inc. | Buy | 10,000 | $13.30 | $133.0K Buy | Form 4 ↗ |
| Jun 22, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | EVMN Evommune, Inc. | Sale | 1,488 | $22.50 | $33.5K Sale | Form 4 ↗ |
| Jun 22, 2026 | Drew Janice Suzann Chief of Dev. Operations | EVMN Evommune, Inc. | Sale | 20,000 | $22.63 | $452.6K Sale | Form 4 ↗ |
| Jun 22, 2026 | Luis C. Pena President & CEO, Director | EVMN Evommune, Inc. | Sale | 7,438 | $22.71 | $168.9K Sale | Form 4 ↗ |
| Jun 2, 2026 | David E. Cohen Director | EVMN Evommune, Inc. | Sale | 600 | $21.38 | $12.8K Sale | Form 4 ↗ |
| Jun 2, 2026 | David E. Cohen Director | EVMN Evommune, Inc. | Sale | 5,456 | $20.21 | $110.3K Sale | Form 4 ↗ |
| Jun 1, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | EVMN Evommune, Inc. | Sale | 16,687 | $22.74 | $379.5K Sale | Form 4 ↗ |
| Jun 1, 2026 | Luis C. Pena President & CEO, Director | EVMN Evommune, Inc. | Sale | 16,787 | $22.74 | $381.7K Sale | Form 4 ↗ |
| May 28, 2026 | Kyle Carver Chief Financial Officer | EVMN Evommune, Inc. | Sale | 18,175 | $22.84 | $415.1K Sale | Form 4 ↗ |
| May 28, 2026 | Gregory S. Moss Chief Business & Legal Officer | EVMN Evommune, Inc. | Sale | 14,223 | $22.83 | $324.7K Sale | Form 4 ↗ |
| Dec 19, 2025 | Robert Lorne Hopfner Director, 10% owner | EVMN Evommune, Inc. | Buy | 1,000 | $17.35 | $17.4K Buy | Form 4 ↗ |
| Nov 7, 2025 | Weegen Felice Isabel Verduyn-van Director, 10% owner | EVMN Evommune, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Nov 7, 2025 | LSP 7 Cooperative UA 10% owner | EVMN Evommune, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Nov 7, 2025 | Ra Capital Management, L.P. Director, 10% owner | EVMN Evommune, Inc. | Buy | 92,904 | $16.00 | $1.5M Buy | Form 4 ↗ |
| Nov 7, 2025 | Ra Capital Management, L.P. Director, 10% owner | EVMN Evommune, Inc. | Buy | 1.16M | $16.00 | $18.5M Buy | Form 4 ↗ |
16 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances